Bernstein says the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests met late yesterday to make recommendations on pricing for new and reconsidered laboratory tests in 2025. In the meeting, members of the panel voted on the recommended pricing options with Exact Sciences’ vote the most anticipated, as the company seeks better pricing for Cologuard Plus versus its legacy Cologuard test, the analyst tells investors in a research note. The firm believes results of the panel discussion do not bode well for Exact with the “default” recommendation the panel was left with before the vote was a 0% price increase. This is a negative data point for Exact, according to Bernstein.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- CMS proposal would be positive for Guardant Health, says Craig-Hallum
- Exact Sciences price target lowered to $72 from $80 at Evercore ISI
- Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls
- Scotiabank starts Exact Sciences with Outperform, sees ‘plenty of runway’
- Exact Sciences initiated with an Outperform at Scotiabank